The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

Yazar: Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Yayımlandı Oncoimmunology (2019)

DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients

Yazar: Allera-Moreau, C, Rouquette, I, Lepage, B, Oumouhou, N, Walschaerts, M, Leconte, E, Schilling, V, Gordien, K, Brouchet, L, Delisle, M B, Mazieres, J, Hoffmann, J S, Pasero, P, Cazaux, C
Baskı/Yayın Bilgisi 2012

Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months

Yazar: Noel-Savina, E., Viatgé, T., Faviez, G., Lepage, B., Mhanna, L.t, Pontier, S., Dupuis, M., Collot, S., Thomas, P., Idoate Lacasia, J., Crognier, L., Bouharaoua, S., Silva Sifontes, S., Mazieres, J., Prévot, G., Didier, A.
Yayımlandı Respir Med Res (2021)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

Yazar: Raynaud, C., Greillier, L., Mazieres, J., Monnet, I., Mastroianni, B., Robinet, G., Fraboulet, G., Dixmier, A., Berard, H., Lamy, R., Letreut, J., Lena, H., Oliviero, G., Botta, S., Vergnenegre, A., Borget, I., Chouaid, C.
Yayımlandı BMC Cancer (2015)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Yazar: Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Yayımlandı Ann Oncol (2018)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

Yazar: Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazières, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A.-C., Westeel, V., Wislez, M.
Yayımlandı Respir Med Res (2020)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)(†)

Yazar: Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., Kim, J.-H., Mazieres, J., Kim, S.-W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., Jänne, P. A.
Yayımlandı Ann Oncol (2015)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Yazar: Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Yayımlandı Ann Oncol (2019)